USFDA approves world’s first Chikungunya vaccine Ixchitq developed by French Biotech company Valneva

he US Food and Drug Administration (FDA) has approved the world's first chikungunya vaccine. The vaccine Ixchiq, developed by French biotech company Valneva, is approved for individuals 18 years of age and older, who are at increased risk of exposure to chikungunya virus. Ixchiq is administered as a single dose by injection into the muscle.